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Abstract
Background: Studies in the past have shown that perforin expression is up-regulated during acute renal rejection, which
provided hopes for a non-invasive and reliable diagnostic method to identify acute rejection. However, a systematic
assessment of the value of perforin as a diagnostic marker of acute renal rejection has not been performed. We conducted
this meta-analysis to document the diagnostic performance of perforin mRNA detection and to identify potential variables
that may affect the performance.
Methodology/Principal Findings: Relevant materials that reported the diagnostic performance of perforin mRNA detection
in acute renal rejection patients were extracted from electronic databases. After careful evaluation of the studies included in
this analysis, the numbers of true positive, true negative, false positive and false negative cases of acute renal rejection
identified by perforin mRNA detection were gathered from each data set. The publication year, sample origin, mRNA
quantification method and housekeeping gene were also extracted as potential confounding variables. Fourteen studies
with a total of 501 renal transplant subjects were included in this meta-analysis. The overall performance of perforin mRNA
detection was: pooled sensitivity, 0.83 (95% confidence interval: 0.78 to 0.88); pooled specificity, 0.86 (95% confidence
interval: 0.82 to 0.90); diagnostic odds ratio, 28.79 (95% confidence interval: 16.26 to 50.97); and area under the summary
receiver operating characteristic curves value, 0.910760.0174. The univariate analysis of potential variables showed some
changes in the diagnostic performance, but none of the differences reached statistical significance.
Conclusions/Significance: Despite inter-study variability, the test performance of perforin mRNA detected by polymerase
chain reaction was consistent under circumstances of methodological changes and demonstrated both sensitivity and
specificity in detecting acute renal rejection. These results suggest a great diagnostic potential for perforin mRNA detection
as a reliable marker of acute rejection in renal allograft recipients.
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Introduction
Renal transplantation has been the treatment of choice for
patients with end-stage renal disease (ESRD) for decades.
However, although novel and powerful immunosuppressive drugs
have been developed, acute rejection (AR) remains a major cause
of allograft dysfunction and allograft failure [1,2]. Even a single
episode of AR can be a strong predictor of graft failure [3].
Currently, the diagnosis of AR is established based on
histological evaluation of allograft biopsy samples. However,
biopsy is an invasive procedure that may cause biopsy-
associated complications such as perirenal hematoma, hematuria
and infection [4,5], which restrict its application for serial
surveillance testing. In addition, sampling error and the
variability of the pathological changes of AR make it difficult
to make definitive diagnoses based on renal biopsy in many
cases [6]. Other methods such as ultrasonography and serum
creatinine measurements can be indicative of ARbut cannot
reach a conclusive diagnosis [7,8]. Therefore, developing
a reliable, specific and non-invasive diagnostic method for
identifying ARwould be of great help to improve clinical
practice in renal transplantation.
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e39610Since allograft infiltration by T lymphocytes is a distinctive
feature of rejection, analyzing the expression of specific genes
involved in T cell activation provides a new option for AR
diagnosis. Among the numerous cell subsets that infiltrate the graft
site, cytotoxic T lymphocytes (CTL) are one of the major effector
cells during the AR response. Lipman et al. [9] and Suthanthiran
et al. [10] revealed a significant increase in transcription of the
gene encoding perforin, one of the predominant effector molecules
of CTLs [11], in allograft biopsy samples from AR patients using
polymerase chain reaction (PCR) techniques. Since that time,
many studies had been conducted to validate this approach for AR
diagnosis in the clinic, and the samples collected for analysis have
been expanded from allograft biopsy samples to less invasive
peripheral blood leukocytes (PBL) and urine samples.
Although increased levels of perforin mRNA were a common
finding during AR in a series of studies [12–14], controversy still
exists regarding the clinical utility of this test due to the single study
design of the previous work and the variable laboratory
methodology used to perform the test among the different studies.
Herein, we performed a meta-analysis to document the diagnostic
performance of perforin mRNA detection in the identification of
AR and try to determine its clinical utility by seeking the potential
variables that may affect the performance of this test. These data
provide important insights that inform clinical physicians re-
garding the diagnosis of AR in renal transplantation.
Materials and Methods
Study Protocol
This analysis was conducted in accordance with a predeter-
mined protocol following the recommendations of Deeks et al.
[15]. The data collection and reporting were in accordance with
Preferred Reporting Items for Systematic Reviews and Meta-
Analyses: The PRISMA Statement (Table S1).
Search Strategy
Relevant materials in the scientific literature were searched in
electronic databases including MEDLINE, EMBASE and the
Cochrane Database of Systematic Reviews prior to December 1st,
2011, without date or language limitations. The following
combinations of key words were used to search for related studies:
‘‘perforin’’ AND (‘‘renal transplant’’ OR ‘‘renal transplantation’’
OR ‘‘kidney transplant’’ OR ‘‘kidney transplantation’’) AND
‘‘rejection.’’ The electronic searching was supplemented by
checking reference lists from the identified articles for additional
original reports.
Inclusion and Exclusion Criteria
Studies were included if they fulfilled the following criteria: (1)
Two comparison groups of patients were necessary for every study:
AR group and non-rejection group. (2) Patient samples were
diagnosed as AR or non-rejection based on the histological
evidence according to Banff classification. (3) Quantitative de-
tection of perforin mRNA expression level was accomplished by
PCR techniques. (4) The mRNA detection was conducted either at
the same time as biopsy pathological evaluation or immediately
after with the samples being frozen for preservation during the
evaluation. (5) The expression level of perforin was compared to
the chosen housekeeping genes which were expressed at a constant
level in samples from different patient groups. (6) A specific cutoff
value was set to interpret the perforin mRNA results as positive or
negative for AR (for those studies which defined the results as
‘‘detectable’’ or ‘‘undetectable,’’ ‘‘detectable’’ results were re-
garded as positive and vice versa).
The following types of studies were excluded from this meta-
analysis: (1) Works designated as conference abstracts, letters, case
reports, editorials or reviews. (2) Studies only involving pediatric
patients.
Assessment of Study Quality
The quality of each study’s methodology was assessed using the
14-item Quality Assessment of Diagnostic Accuracy Studies
(QUADAS) list [16]. Each question was assigned with a response
of yes, no, or unclear when evaluating each of the included studies.
Since the assessment of quality related strongly to the reporting of
results, a well conducted study could score poorly if the methods
and results were not reported in sufficient detail. Therefore, we did
not report the assessment in scores but in descriptive forms only.
Publication bias was tested using funnel plots and the Egger test
by Stata statistical software (STATA) version 11.0 [17]. An
asymmetric distribution of data points in the funnel plot and
a quantified result of P,0.05 in the Egger test indicated the
presence of potential publication bias [18].
Data Extraction
The following data were extracted from each eligible study: year
of publication, sample origin, mRNA quantification method,
housekeeping gene, and the number of true positive (TP), false
positive (FP), false negative (FN) and true negative (TN) cases of
AR identified by perforin mRNA levels. All subjects who displayed
biopsy results with any degree of AR defined by Banff classification
were assigned to the rejection group, regardless of cellular or
humoral rejection. The subjects with biopsies showing no evidence
of any types of rejection, including normal tissues and tissues with
non-rejection pathological changes, were assigned to the non-
rejection group. The selected articles were assessed by two
reviewers (YS and XL), independently. Disagreements were
resolved by consultation with a third reviewer (ZG).
Statistical Analysis
Data were analyzed using Meta-Disc Version 1.4 [19] and
STATA version 11.0. The test performance of perforin mRNA
detection for the identification of ARwas measured by the
following indicators: sensitivity, specificity and diagnostic odds
ratio (DOR). Sensitivity was represented by the proportion of AR
cases that were correctly identified by the positive results of
perforin mRNA levels. Specificity was represented by the pro-
portion of non-rejection cases that were correctly identified by the
negative results of perforin mRNA levels [20]. As different cutoff
values were used in each study, there was the potential for
a threshold effect which would affect the conclusions of this
analysis. Therefore, it was more reliable to define the summary of
test performance using DOR than simply pooling sensitivity and
specificity together across the studies. DOR was an independent
indicator ranging from 0 to infinity, which represented how much
greater the odds of having AR were for patient with a positive
perforin mRNA result than for patient with a negative perforin
mRNA result. The higher the DOR, the better the discriminatory
ability of the test was [21].
The summary receiver operating characteristic (SROC) curve
was plotted based on the combination of sensitivity and specificity,
and the area under the curve (AUC) value was then calculated as
a global measurement of test performance. The closer the AUC
was to 1, the better the test performance [22].
Because of potential heterogeneity between studies, effect sizes
were pooled by random-effects models of DerSimonian and Laird
in Meta Disc [23]. Empty cells were handled using a 0.5 continuity
correction.
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The x
2 test was used to examine heterogeneity in pooling
sensitivity and specificity. The Cochran Q test was used to
examine heterogeneity in pooling DOR. Heterogeneity was
considered to be statistically significant when P,0.05 in these
qualitative tests. We also conducted the I
2 test in every pooling
analysis to quantitatively estimate the proportion of total variation
across studies that was attributable to heterogeneity rather than
chance. The I
2 value would range from 0 to 100%, with a value
over 50% indicating significant heterogeneity.
The existence of a threshold effect would manifest as
a curvilinear shape in the SROC curves. In addition, we used
a Spearman correlation analysis to confirm the absence or
presence of a threshold effect by looking for an inverse relationship
between sensitivity and specificity. A value of P,0.05 would
indicate a significant threshold effect was present [24].
Sensitivity Analysis
To determine whether any single study was incurring undue
weight in the analysis, we systematically removed one set of study
data and checked the pooled results for the remaining studies to
see if they changed significantly. The sensitivity analysis was
conducted for every study.
Univariate Analysis
To identify the sources of potential heterogeneity that
influenced the results of this analysis, a univariate analysis was
conducted. Based on the literature review, the following factors
were chosen as potential variables that may have influenced the
test performance: year of publication, sample type, mRNA
quantification method and housekeeping gene selection. Data sets
were stratified based on these factors and the test performance
would be compared between subgroups using the DOR values and
the AUC of the SROC curves as the major parameters. The
comparison was conducted using random-effects models in
STATA. A value of P,0.05 in the comparison of DOR indicated
a significant change in the test performance due to the covariate.
Results
Literature Search and Characteristics of the Included
Studies
After the primary search of the electronic databases for
published work on the subject, 202 studies were identified. Of
these studies, 123 were excluded after further review of the title
and abstract for irrelevant topics, and an additional 19 were
excluded for duplication of the reports, which left 60 studies
undergoing full text review. The detailed process of this literature
search is shown in Figure 1.
After careful review, 14 studies with a total of 501 subjects were
included in this meta-analysis. In 2 studies [25,26], perforin
expression was detected in both graft biopsy and PBL samples. In
another study [27], perforin expression was detected in both PBL
and urine samples. We decided to retrieve each group as an
independent data set for a total of 17 data sets included in this
analysis. The characteristics of each included study are shown in
Table 1.
Study Quality
We used the QUADAS list of questions to review the test quality
of the included studies. Most of the studies satisfied a majority of
the items on the QUADAS list. The most common missing items
in the studies included in this analysis were reports of intermediate
results and withdrawn cases. In addition, some of the studies failed
to mention the blinded interpretations between the PCR results
and the histological evaluation (Table S2).
The Egger test revealed the possibility of significant publication
bias among the included reports (P=0.008). The funnel plot in
Figure S1 also presented a certain degree of asymmetry, indicating
the potential for publication bias among the studies included in
this analysis.
Overall Diagnostic Performance of Perforin Expression
Figure 2 shows the overall diagnostic measurements of perforin
expression in detecting AR. The summary sensitivity was 0.83
[95% confidence interval (CI): 0.78 to 0.88], with individual
sensitivities ranging from 0.50 to 1.00. The summary specificity
was 0.86 (95% CI: 0.82 to 0.90), with individual specificities
ranging from 0.50 to 1.00. Both pooled estimations showed
significant heterogeneity (Sensitivity: P=0.0041, x
2=34.92,
I
2=54.2%; specificity: P=0.022, x
2=29.35, I
2=45.5%).
The pooled DOR and the SROC curves based on summary
sensitivity and specificity across all data sets are shown in Figure 3.
The pooled DOR was 28.79 (95% CI: 16.26 to 50.97), with
individual DORs ranging from 4.67 to 241.44. The results of
DOR showed consistency accross the included reports, without
noticeable heterogeneity (P=0.74, Cochran-Q=12.05,
I
2=0.0%). The point size in the SROC curve represented the
proportional study weight. Most data gathered near the top left
corner where sensitivity and specificity were both the highest. The
AUC value was 0.910760.0174.
Although we did not notice a curvilinear shape distribution of
the data in the SROC curve, the Spearman correlation analysis
revealed a significant result (P=0.032), suggesting the potential
presence of a threshold effect.
Sensitivity Analysis
We systematically removed one data set at a time and
recalculated the DOR and AUC values for the remaining studies.
The largest change occurred when removing the data set from
Sabek et al. [28], which changed the pooled DOR from 28.79 to
35.68 (+23.9%), and the corresponding change in AUC value was
from 0.9107 to 0.9228 (+1.33%). The second largest change
occurred when removing the urine subgroup from Dias et al. [27],
which changed the pooled DOR from 28.79 to 26.54 (27.81%)
and the corresponding AUC value from 0.9107 to 0.9058
(20.54%). These results indicated that no single data set carried
enough weight to significantly influence the pooled test perfor-
mance reported for the ability of perforin mRNA detection to
identify cases of acute renal rejection.
Univariate Analysis
Publication year. Based on the year of publication of the
studies included in this analysis, we divided the data sets into two
subgroups: those reported prior to the year 2000 and those
reported after the year 2000 (including studies published in 2000).
This time point was chosen because significant progress was made
in the PCR technology and experimental methodology at the
beginning of the 21st century, which may have had an effect on
the perforin mRNA detection performance. We noticed a remark-
able difference in the amount of publications in each subgroup.
Only 4 reports were published prior to 2000 [9,26,29,30], one of
them contained 2 data sets which made it 5 data sets in this
subgroup. The remaining 10 reports (12 data sets) were published
after 2000 [25,27,28,31–37]. The DOR of studies before the year
2000 was 43.52 while the DOR of studies after 2000 was 24.90.
The difference was not statistically significant (P=0.59).
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types of samples: allograft biopsy tissue, PBL and urine. The
biopsy subgroup contained 6 data sets [9,25,26,29,30,37], the PBL
subgroup contained 7 data sets [25–27,28,34–36], and the urine
subgroup contained 4 data sets [27,31–33]. The DORs were
35.11, 21.32, 36.76 for biopsy group, PBL group and urine group,
respectively. However, the difference in DORs did not reach
a level of statistical significance (P=0.77).
Figure 1. Flow chart describing the literature search conducted for this meta-analysis.
doi:10.1371/journal.pone.0039610.g001
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PLoS ONE | www.plosone.org 4 June 2012 | Volume 7 | Issue 6 | e39610Messenger RNA quantification method. There were 3
different PCR techniques used in the included studies to quantify
perforin mRNA: 8 data sets used reverse transcriptase PCR (RT-
PCR) [25,27,28,31,36,37], 6 data sets used competitive RT-PCR
[9,26,29,30,34], and 3 data sets used real-time quantitative RT-
PCR [32,33,35]. The DOR was 25.23 for RT-PCR, 37.94 for
competitive RT-PCR and 33.35 for real-time quantitative RT-
PCR. The difference between the three techniques was not
statistically significant (P=0.89).
Housekeeping gene. Four different housekeeping genes
were used as the standard expression in the included studies to
measure the relative expression level of perforin: cyclophilin for 4
data sets [27,31–33], b-actin for 5 [25,27,34,36], 18s rRNA for 2
[28,35], and glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) for 6 [9,26,29,30,37]. The DOR was 36.76 for
cyclophilin group, 34.38 for b-actin group, 12.03 for 18s rRNA
group and 33.45 for GAPDH group. However, the result was not
statistically significant either (P=0.95).
Table 2 summarizes the results of univariate analysis.
Discussion
Since the middle of the 20
th century, great success has been
made in renal transplantation with the progress in surgical
techniques, expanded organ sources, organ preservation tech-
niques, novel immunosuppressants and management of compli-
cations. However, transplant patients are still facing many
challenges, among which AR draws the greatest attention.
Despite the fact that histological evaluation for AR has been
well defined in guidelines such as Banff criteria [38] and
Cooperative Clinical Trials in Transplantation (CCTT) criteria
[39], novel and less invasive methods are still required to
improve the diagnostic evaluation of AR. The effector molecules
of CTLs such as perforin, granzyme B, Fas and Fas ligand are
potential diagnostic markers for AR, especially when they can
be detected in samples such as PBLs and urine that do not
require invasive procedures to obtain. The major objectives of
conducting this meta-analysis were to explore the diagnostic
performance of perforin mRNA expression in AR and to
determine its clinical utility. To our knowledge, this is the first
pooled estimation of the diagnostic performance of perforin
mRNA detection for the evaluation of AR in renal transplant
recipients.
In this meta-analysis, we included 14 relevant studies with a total
of 501 subjects. Although results were not consistent across the
different studies, the overall diagnostic performance of detecting
perforin mRNA in kidney transplant patients showed pooled
sensitivity and specificity of 0.83 (95% CI: 0.78 to 0.88) and 0.86
(95% CI: 0.82 to 0.90), respectively. The pooled DOR and AUC
of the SROC curves for all data sets were 28.79 (95% CI: 16.26 to
50.97) and 0.910760.0174, respectively. These results represented
a good diagnostic efficacy for perforin mRNA detection in
identifying AR, regardless of the sample origin and methodology
variation. Furthermore, to investigate potential variables that
might have influenced the diagnostic performance, we conducted
a univariate analysis trying to provide clues for methodology
standardization. In this analysis, none of the chosen factors
appeared to have a significant effect on the diagnostic perfor-
mance. This lack of variation from the chosen factors may be due
to the small sample sizes of the included data sets since this
diagnostic method had not been widely used in transplant centers.
In addition, the perforin gene sequences used in the included
reports were not uniform, which could be another potentail source
of variation that may have influenced test performance. However,
Table 1. Study characteristics of each included study.
Reference
number Author
Publication
year Sample origin
Messenger RNA
quantification method
Housekeeping
gene
Number
of
subjects Test results
TP FP FN TN
9 Lipman et al. 1994 graft biopsy competitive RT-PCR GAPDH 26 9 2 1 14
25 Netto et al. 2002 graft biopsy RT-PCR b-actin 29 4 1 3 21
PBL RT-PCR b-actin 29 6 0 1 22
26 Vasconcellos et al. 1998 graft biopsy competitive RT-PCR GAPDH 31 11 2 0 18
PBL competitive RT-PCR GAPDH 31 9 3 2 17
27 Dias et al. 2008 PBL RT-PCR cyclophilin 48 20 7 0 21
urine RT-PCR cyclophilin 50 20 4 0 26
28 Sabek et al. 2002 PBL RT-PCR 18s rRNA 27 5 5 3 14
29 Lipman et al. 1998 graft biopsy competitive RT-PCR GAPDH 21 6 0 5 10
30 Strehlau et al. 1997 graft biopsy competitive RT-PCR GAPDH 27 12 1 3 11
31 Li et al. 2001 urine RT-PCR cyclophilin 44 20 3 4 17
32 Øzbay et al. 2009 urine real-time quantitative RT-PCR cyclophilin 41 21 4 3 13
33 Galante et al. 2006 urine real-time quantitative RT-PCR cyclophilin 24 11 1 2 10
34 Shin et al. 2005 PBL competitive RT-PCR b-actin 15 5 1 2 7
35 Simon et al. 2003 PBL real-time quantitative RT-PCR 18s rRNA 16 4 0 1 11
36 Dugr’e et al. 2000 PBL RT-PCR b-actin 21 4 1 4 12
37 Dias et al. 2004 graft biopsy RT-PCR GAPDH 21 10 5 1 5
Abbreviations: TP, true positive; FP, false positive; FN, false negative; TN, true negative; PBL, peripheral blood leukocyte; RT-PCR, reverse transcription polymerase chain
reaction; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
doi:10.1371/journal.pone.0039610.t001
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PLoS ONE | www.plosone.org 5 June 2012 | Volume 7 | Issue 6 | e39610the limited number of data sets using each perforin sequence
restricted us from categorizing the studies into subgroups for the
univariate analysis.
In several clinical studies during the 1990s [9,10,30], cytotoxic
gene expression was found to be up-regulated in allografts during
AR. However, these discoveries had limited impact as diagnostic
Figure 2. Sensitivity and specificity of perforin mRNA detection for the diagnosis of AR. (A) Pooled sensitivity. (B) Pooled specificity. Effect
sizes were pooled by random-effects models. The point estimates from each study are shown as solid squares. The pooled estimates are shown as
a solid diamond. Error bars represent 95% CIs.
doi:10.1371/journal.pone.0039610.g002
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PLoS ONE | www.plosone.org 6 June 2012 | Volume 7 | Issue 6 | e39610Figure 3. Overall DOR and SROC curves for all data sets describing the diagnostic performance of perforin mRNA detection in
identifying AR. (A) Overall DOR. (B) The SROC curves for all data sets. Effect sizes were pooled by random-effects models. The pooled DOR is shown
as a solid diamond. Each square in the SROC curve represents one study. Sample size is indicated by the size of the square.
doi:10.1371/journal.pone.0039610.g003
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time. More recently, given the fact that lymphocytes would
infiltrate the kidneys during AR and present in urine sediment
cells, Li et al. [31] explored the utilization of perforin mRNA
detection in urine cells as a non-invasive diagnostic marker of AR.
Subsequent studies conducted in other centers confirmed the
feasibility of this approach [32,33]. Although in our analysis, the
diagnostic performance of urine sample didn’t stand out partic-
ularly, the result was still encouraging since it brought hope for
a non-invasive method for the diagnosis of AR which was as
reliable as biopsy sample.
Debates about the application of urine perforin detection
mainly focus on the differential diagnosis between rejection and
other complications such as delayed graft function (DGF) and
urinary tract infection (UTI). In the study conducted by Yannaraki
et al. [14], an increase in perforin mRNA was found in both the
AR group and the UTI group. Their experience suggested
a significant overlap of perforin mRNA levels in different clinical
conditions, which made it difficult to establish a threshold value for
differential diagnosis. Øzbay et al. [32] reported similar results
when trying to differentiate AR from bacteriuria. This may be
explained by the similar cytolytic response of the activated T
lymphocytes during both rejection and infection. In three of the 4
included studies in the urine subgroup of this meta-analysis [31–
33], the non-rejection samples were composed of stable grafts only,
while in the other study [27], the non-rejection samples contained
chronic allograft nephropathy, toxic tubulopathy, nonspecific
changes, acute tubular necrosis and renal-vein thrombosis. The
non-rejection controls in other included studies also contained
samples with multiple other types of kidney dysfunction other than
graft rejection, which did not allow us to carry out a meta-analysis
of the differential diagnostic performance of perforin. Therefore,
we could not conclude that a high perforin expression level would
definitely point to the diagnosis of AR, which would require
supplemental laboratory tests to rule out other complications.
Although urine is the ideal choice for a non-invasive procedure,
there are some potential limitations to this approach. Most
importantly, the test depends on urine production. This limits the
utilization in patients under anuric conditions which can appear
during AR, acute tubular necrosis (ATN), DGF, as well as other
conditions. In the study conducted by Dias et al. [27], nearly 20%
of the patients were unable to provide sufficient urine samples for
analysis. Given these circumstances, the evaluation of perforin
mRNA levels in PBLs and allografts are important alternatives. An
increase in perforin mRNA can help clinical decision-making for
early enhanced immunosuppression intervention before histolog-
ical evidence of substantial damage develops, and a decrease in
perforin mRNA levels may provide an indication of response to
therapy.
There are several limitations in this meta-analysis. First,
qualities of the included studies were not uniform. The essential
demographical data like age and gender distributions were missing
in some studies, which might be a potential heterogeneity source in
the analysis. Also, the specific cut-off values for the mRNA level
were not provided in most of the studies. In addition, only 14
studies met the inclusion criteria in this analysis. The small sample
size limited the generalization of the results and did not allow us to
test the differential diagnostic performance of perforin mRNA
detection. All these limitations provide room for future evaluation.
In conclusion, the test performance of perforin mRNA detected
by PCR techniques was impressive and consistent under
circumstances of methodological changes. The test in urine stood
out as a potential novel and non-invasive method for the reliable
diagnosis of AR, or at least as an indicator that a biopsy is
warranted. Prospective studies with larger sample sizes would
reinforce the findings revealed in the current meta-analysis and
may be able to reveal how perforin mRNA detection would help
to differentiate between diagnoses that are clinically similar to AR,
providing more conclusive evidence for its clinical utility in the
evaluation of renal transplant recipients.
Table 2. Univariate analysis of potential variables influencing the test performance of perforin during AR.
Variables Subgroups
Number of
independent
data sets Sensitivity (95% CI) Specificity (95% CI) DOR (95% CI) AUC
Publication year before 2000 5 0.81 (0.69–0.90) 0.90 (0.81–0.95) 43.52 (14.19–133.46) 0.9406
after 2000 12 0.84 (0.78–0.90) 0.85 (0.79–0.89) 24.90 (12.82–48.37) 0.9028
Sample origin graft biopsy 6 0.80 (0.68–0.89) 0.88 (0.79–0.94) 35.11 (12.02–102.56) 0.9210
PBL 7 0.80 (0.69–0.89) 0.86 (0.78–0.92) 21.32 (7.97–57.09) 0.9028
urine 4 0.89 (0.80–0.95) 0.85 (0.75–0.92) 36.76 (13.59–99.39) 0.9158
PCR techniques RT-PCR 8 0.85 (0.76–0.91) 0.84 (0.78–0.89) 25.23 (9.59–66.37) 0.9056
competitive RT-PCR 6 0.80 (0.68–0.89) 0.90 (0.81–0.95) 37.94 (13.51–106.56) 0.9370
real-time quantitative RT-PCR3 0.86 (0.71–0.95) 0.87 (0.73–0.96) 33.35 (9.26–120.09) 0.9196
Housekeeping gene cyclophilin 4 0.89 (0.80–0.95) 0.85 (0.75–0.92) 36.76 (13.59–99.39) 0.9158
b-actin 5 0.80 (0.66–0.90) 0.89 (0.81–0.95) 34.38 (10.16–116.35) 0.9372
18s rRNA 2 0.69 (0.39–0.91) 0.83 (0.65–0.94) 12.03 (0.96–151.24) unavailable
a
GAPDH 6 0.83 (0.72–0.91) 0.85 (0.76–0.92) 33.45 (12.12–92.34) 0.9194
All 17 0.83 (0.78–0.88) 0.86 (0.82–0.90) 28.79 (16.26–50.97) 0.9107
aThree independent data points are required at least to draw an SROC curve.
Abbreviations: DOR, diagnostic odds ratio; CI, confidence interval; AUC, area under the curve of the SROC curve; PBL, peripheral blood leukocyte; PCR, polymerase chain
reaction; RT-PCR, reverse transcription polymerase chain reaction; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
doi:10.1371/journal.pone.0039610.t002
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